1191. Interactive Panelist
Session: Interactive Session: Direct Acting Antivirals for HCV: State-of-the-Art
Friday, October 19, 2012: 3:00 PM
Room: Ballroom 20 ABCD
David Wyles, MD, Medicine, University of California San Diego, La Jolla, CA

David Wyles, M.D. is an Associate Professor of Medicine in the Division of Infectious Diseases at the University of California, San Diego. His research interests including the in vitro assessment of novel inhibitors of Hepatitis C virus (HCV) replication, clinical trials of HCV antivirals, and HIV-HCV co-infection. Dr. Wyles completed his Infectious Diseases fellowship at the University of Colorado Health Sciences Center in 2004. Dr Wyles was subsequently recruited to the University of California, San Diego where he has continued to work on in vitro systems to characterize novel anti-HCV compounds. He is a Principal or Co-Investigator on several NIH grants to study in vitro HCV replications system, novel HCV antivirals, and sexual transmission of HCV in HCV/HIV co-infected individuals. Dr. Wyles is also involved in clinical research trials of novel agents for the treatment of HCV in both mono-infected and co-infected patients.
Clinically Dr. Wyles helped initiate a Hepatitis-HIV co-infection clinic within the HIV clinic at University of Colorado. Currently, Dr. Wyles is an Attending Physician in the Owen Clinic HIV- hepatitis co-infection clinic as well as on the inpatient Infectious Disease and Internal Medicine services at the University of California, San Diego.
Dr. Wyles is a member of the Infectious Diseases Society of America. He is a core faculty member of the International AIDS Society-USA and serves on the AIDS Clinical Trials Group (ACTG) Hepatitis Transformative Science Group.



Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 17th with the exception of research findings presented at the IDWeek press conferences.